Cargando…
Characterization of clinically used oral antiseptics as quadruplex-binding ligands
Approaches to characterize the nucleic acid-binding properties of drugs and druglike small molecules are crucial to understanding the behavior of these compounds in cellular systems. Here, we use a Small Molecule Microarray (SMM) profiling approach to identify the preferential interaction between ch...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888870/ https://www.ncbi.nlm.nih.gov/pubmed/29481610 http://dx.doi.org/10.1093/nar/gky084 |
_version_ | 1783312614557745152 |
---|---|
author | Calabrese, David R Zlotkowski, Katherine Alden, Stephanie Hewitt, William M Connelly, Colleen M Wilson, Robert M Gaikwad, Snehal Chen, Lu Guha, Rajarshi Thomas, Craig J Mock, Beverly A Schneekloth, John S |
author_facet | Calabrese, David R Zlotkowski, Katherine Alden, Stephanie Hewitt, William M Connelly, Colleen M Wilson, Robert M Gaikwad, Snehal Chen, Lu Guha, Rajarshi Thomas, Craig J Mock, Beverly A Schneekloth, John S |
author_sort | Calabrese, David R |
collection | PubMed |
description | Approaches to characterize the nucleic acid-binding properties of drugs and druglike small molecules are crucial to understanding the behavior of these compounds in cellular systems. Here, we use a Small Molecule Microarray (SMM) profiling approach to identify the preferential interaction between chlorhexidine, a widely used oral antiseptic, and the G-quadruplex (G4) structure in the KRAS oncogene promoter. The interaction of chlorhexidine and related drugs to the KRAS G4 is evaluated using multiple biophysical methods, including thermal melt, fluorescence titration and surface plasmon resonance (SPR) assays. Chlorhexidine has a specific low micromolar binding interaction with the G4, while related drugs have weaker and/or less specific interactions. Through NMR experiments and docking studies, we propose a plausible binding mode driven by both aromatic stacking and groove binding interactions. Additionally, cancer cell lines harbouring oncogenic mutations in the KRAS gene exhibit increased sensitivity to chlorhexidine. Treatment of breast cancer cells with chlorhexidine decreases KRAS protein levels, while a KRAS gene transiently expressed by a promoter lacking a G4 is not affected. This work confirms that known ligands bind broadly to G4 structures, while other drugs and druglike compounds can have more selective interactions that may be biologically relevant. |
format | Online Article Text |
id | pubmed-5888870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58888702018-04-11 Characterization of clinically used oral antiseptics as quadruplex-binding ligands Calabrese, David R Zlotkowski, Katherine Alden, Stephanie Hewitt, William M Connelly, Colleen M Wilson, Robert M Gaikwad, Snehal Chen, Lu Guha, Rajarshi Thomas, Craig J Mock, Beverly A Schneekloth, John S Nucleic Acids Res Chemical Biology and Nucleic Acid Chemistry Approaches to characterize the nucleic acid-binding properties of drugs and druglike small molecules are crucial to understanding the behavior of these compounds in cellular systems. Here, we use a Small Molecule Microarray (SMM) profiling approach to identify the preferential interaction between chlorhexidine, a widely used oral antiseptic, and the G-quadruplex (G4) structure in the KRAS oncogene promoter. The interaction of chlorhexidine and related drugs to the KRAS G4 is evaluated using multiple biophysical methods, including thermal melt, fluorescence titration and surface plasmon resonance (SPR) assays. Chlorhexidine has a specific low micromolar binding interaction with the G4, while related drugs have weaker and/or less specific interactions. Through NMR experiments and docking studies, we propose a plausible binding mode driven by both aromatic stacking and groove binding interactions. Additionally, cancer cell lines harbouring oncogenic mutations in the KRAS gene exhibit increased sensitivity to chlorhexidine. Treatment of breast cancer cells with chlorhexidine decreases KRAS protein levels, while a KRAS gene transiently expressed by a promoter lacking a G4 is not affected. This work confirms that known ligands bind broadly to G4 structures, while other drugs and druglike compounds can have more selective interactions that may be biologically relevant. Oxford University Press 2018-04-06 2018-02-22 /pmc/articles/PMC5888870/ /pubmed/29481610 http://dx.doi.org/10.1093/nar/gky084 Text en Published by Oxford University Press on behalf of Nucleic Acids Research 2018. This work is written by (a) US Government employee(s) and is in the public domain in the US. |
spellingShingle | Chemical Biology and Nucleic Acid Chemistry Calabrese, David R Zlotkowski, Katherine Alden, Stephanie Hewitt, William M Connelly, Colleen M Wilson, Robert M Gaikwad, Snehal Chen, Lu Guha, Rajarshi Thomas, Craig J Mock, Beverly A Schneekloth, John S Characterization of clinically used oral antiseptics as quadruplex-binding ligands |
title | Characterization of clinically used oral antiseptics as quadruplex-binding ligands |
title_full | Characterization of clinically used oral antiseptics as quadruplex-binding ligands |
title_fullStr | Characterization of clinically used oral antiseptics as quadruplex-binding ligands |
title_full_unstemmed | Characterization of clinically used oral antiseptics as quadruplex-binding ligands |
title_short | Characterization of clinically used oral antiseptics as quadruplex-binding ligands |
title_sort | characterization of clinically used oral antiseptics as quadruplex-binding ligands |
topic | Chemical Biology and Nucleic Acid Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888870/ https://www.ncbi.nlm.nih.gov/pubmed/29481610 http://dx.doi.org/10.1093/nar/gky084 |
work_keys_str_mv | AT calabresedavidr characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT zlotkowskikatherine characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT aldenstephanie characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT hewittwilliamm characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT connellycolleenm characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT wilsonrobertm characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT gaikwadsnehal characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT chenlu characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT guharajarshi characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT thomascraigj characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT mockbeverlya characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands AT schneeklothjohns characterizationofclinicallyusedoralantisepticsasquadruplexbindingligands |